Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02090530 · ClinicalTrials.gov registry record
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
A clinical trial of Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT02090530: Recruiting study of Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02090530 is a study of Cancer that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 1,000 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02090530, a study of Cancer, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Primary Outcome
Impact on clinical care
Conditions Studied
Interventions
- OTHER Biospecimen collection
Study Locations (1)
Ohio
- Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2013-11-04 |
| Est. Completion | 2025-12-31 |
What NCT02090530 shows while recruiting
NCT02090530 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen collection is the first listed.
NCT02090530 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02090530 about?
NCT02090530 is a clinical study titled "Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing". Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
What is the current status of trial NCT02090530?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2013-11-04. Estimated completion is 2025-12-31.
What conditions does trial NCT02090530 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT02090530?
The interventions under investigation include: Biospecimen collection (OTHER).
Who is sponsoring clinical trial NCT02090530?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02090530 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02090530's enrollment target sits among peer trials
1,000 80th of 615 higher than 531 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI